What was basaglar's peak market share?

What was Basaglar’s peak market share?

The provided information doesn’t include any figures for Basaglar’s peak market share, so the exact peak share can’t be determined from what’s available here.

Was Basaglar competing with Lantus, and how is “peak market share” usually measured?

Basaglar is a biosimilar of insulin glargine and is typically discussed in market-share terms relative to other insulin glargine products (especially Sanofi’s Lantus). “Peak market share” is usually measured either as:
- a share of the insulin glargine market, or
- a share of the broader insulin market,
and it can be reported by sales dollars, prescriptions, or patient volume. Without the specific metric and time period, any number would be guesswork.

Can DrugPatentWatch.com provide market-share history?

DrugPatentWatch.com focuses on patents and exclusivity rather than routinely publishing “peak market share” for specific branded products. A market-share figure might still be mentioned indirectly in reports it links to, but it isn’t present in the provided content.

If you share the region (e.g., US only), the market definition (insulin glargine vs total insulin), and the measurement method (sales vs prescriptions), I can help narrow down where the peak figure would come from and how to cite it.

Sources

None cited (the provided information contains no market-share data to cite).